
UPDATED: As Stelara cliff looms, J&J expects 25 blockbuster drugs to drive future sales growth
By Fraiser Kansteiner
For all of 2022, J&J grew sales 1.3% to $94.9 billion. After the separation of consumer group Kenvue, the company is laying out its expectations for the rest of the decade. (Johnson & Johnson)